Kezar Life Sciences, Inc.
KZR
$6.18
$0.030.49%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -57.43% | -41.20% | -- | -29.20% | -31.58% |
| Gross Profit | 57.43% | 41.20% | -- | 29.20% | 2.96% |
| SG&A Expenses | -15.86% | -10.48% | -16.67% | -3.73% | -35.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 33.50% | -- | -- | -- | -- |
| Total Operating Expenses | -45.18% | -33.34% | -25.65% | -24.04% | -31.28% |
| Operating Income | 45.18% | 33.34% | 25.65% | 24.04% | 12.44% |
| Income Before Tax | 44.73% | 36.40% | 23.56% | 37.33% | 12.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.73% | 36.40% | 23.56% | 37.33% | 12.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.73% | 36.40% | 23.56% | 37.33% | 12.08% |
| EBIT | 45.18% | 33.34% | 25.65% | 24.04% | 12.44% |
| EBITDA | 45.56% | 33.66% | 25.90% | 24.20% | 12.51% |
| EPS Basic | 44.93% | 36.63% | 23.83% | -24.89% | 12.42% |
| Normalized Basic EPS | 44.93% | 31.95% | 23.82% | -54.62% | 12.42% |
| EPS Diluted | 44.93% | 36.63% | 23.83% | -24.89% | 12.42% |
| Normalized Diluted EPS | 44.93% | 31.95% | 23.82% | -54.62% | 12.42% |
| Average Basic Shares Outstanding | 0.37% | 0.36% | 0.35% | 0.36% | 0.39% |
| Average Diluted Shares Outstanding | 0.37% | 0.36% | 0.35% | 0.36% | 0.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |